| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency
|
Kung, Charles
|
|
|
130 |
11 |
p. 1347-1356
|
artikel
|
| 2 |
Brentuximab: is it time for a new “B” in ABVD?
|
Stephens, Deborah M.
|
|
|
130 |
11 |
p. 1281-1282
|
artikel
|
| 3 |
Cyclin D1–negative mantle cell lymphoma with aberrant CD3 expression
|
Malek, Anita
|
|
|
130 |
11 |
p. 1388
|
artikel
|
| 4 |
Editorial Board
|
|
|
|
130 |
11 |
p. i
|
artikel
|
| 5 |
Erdheim-Chester disease: the “targeted” revolution
|
Vaglio, Augusto
|
|
|
130 |
11 |
p. 1282-1284
|
artikel
|
| 6 |
Exuberant nodal proliferation of mature plasmacytoid dendritic cells in a patient with chronic myelomonocytic leukemia
|
Wang, Huan-You
|
|
|
130 |
11 |
p. 1387
|
artikel
|
| 7 |
FDG-PET–driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study
|
Casasnovas, R.-O.
|
|
|
130 |
11 |
p. 1315-1326
|
artikel
|
| 8 |
Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma
|
Connors, Joseph M.
|
|
|
130 |
11 |
p. 1375-1377
|
artikel
|
| 9 |
Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugs
|
Farrell, Ann T.
|
|
|
130 |
11 |
p. 1285-1289
|
artikel
|
| 10 |
Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult
|
Morris, Emma C.
|
|
|
130 |
11 |
p. 1327-1335
|
artikel
|
| 11 |
Gene therapy: WAS (not) just for kids
|
Kohn, Donald B.
|
|
|
130 |
11 |
p. 1278-1279
|
artikel
|
| 12 |
Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation
|
Browning, Sabrina
|
|
|
130 |
11 |
p. 1383-1386
|
artikel
|
| 13 |
High-risk DLBCL: interim PET? Not yet
|
Hertzberg, Mark
|
|
|
130 |
11 |
p. 1277-1278
|
artikel
|
| 14 |
How I monitor long-term and late effects after blood or marrow transplantation
|
Bhatia, Smita
|
|
|
130 |
11 |
p. 1302-1314
|
artikel
|
| 15 |
MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts
|
Wallace, Jared A.
|
|
|
130 |
11 |
p. 1290-1301
|
artikel
|
| 16 |
Platelet soluble CD40-ligand level is associated with transfusion adverse reactions in a mixed threshold-and-hit model
|
Cognasse, Fabrice
|
|
|
130 |
11 |
p. 1380-1383
|
artikel
|
| 17 |
Strict tropism for CD71+/CD234+ human reticulocytes limits the zoonotic potential of Plasmodium cynomolgi
|
Kosaisavee, Varakorn
|
|
|
130 |
11 |
p. 1357-1363
|
artikel
|
| 18 |
Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)
|
Cohen Aubart, Fleur
|
|
|
130 |
11 |
p. 1377-1380
|
artikel
|
| 19 |
The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation
|
Mizukawa, Benjamin
|
|
|
130 |
11 |
p. 1336-1346
|
artikel
|
| 20 |
Tissue-type plasminogen activator regulates macrophage activation and innate immunity
|
Mantuano, Elisabetta
|
|
|
130 |
11 |
p. 1364-1374
|
artikel
|
| 21 |
tPA and anger management for macrophages
|
Miles, Lindsey A.
|
|
|
130 |
11 |
p. 1280-1281
|
artikel
|
Tijdschrift beschrijving